Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized patient support program in fingolimod-treated relapsing-remitting multiple sclerosis
2012-002637-11Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Treatment satisfaction. Started Oct 2012; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-002637-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002637-11.